Bionano Genomics (BNGO) Liabilities and Shareholders Equity (2017 - 2026)

Bionano Genomics has disclosed Liabilities and Shareholders Equity across 10 years of filings, most recently posting $64.8 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $64.8 million, down 17.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $293.5 million (down 21.07% YoY), and the FY2025 annual result was $73.6 million, down 4.03% from the prior year.
• Liabilities and Shareholders Equity came in at $64.8 million for Q1 2026 at Bionano Genomics, down from $73.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $348.2 million in Q1 2022 to a low of $64.8 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $158.0 million (2024), against an average of $181.4 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 64.24% in 2024 and decreased 4.03% in 2025, its largest moves.
• Bionano Genomics' Liabilities and Shareholders Equity stood at $307.5 million in 2022, then slumped by 30.28% to $214.4 million in 2023, then slumped by 64.24% to $76.7 million in 2024, then retreated by 4.03% to $73.6 million in 2025, then fell by 11.93% to $64.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $64.8 million (Q1 2026), $73.6 million (Q4 2025), and $79.1 million (Q3 2025), per Business Quant data.